机构：[1]Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, 650 W. Baltimore St., Baltimore, MD21201, USA[2]Department of Thoracic Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Beijing Institute for Cancer Research, Beijing 100142, China[3]Department of Pathology, Johns Hopkins University, Baltimore, MD 21287, USA[4]Department of Thoracic Surgery, Lung Cancer Center, Xuanwu Hospital, Capital Medical University, Beijing 100053, China胸外科首都医科大学宣武医院[5]Guangdong Key Laboratory of Liver Disease Research, Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China
Lung cancer is the leading cause of cancer-related death worldwide. Although advanced drugs have benefitted patients, therapeutic success has largely been hampered because of rapid development of resistance. Here we report that PIWI-interacting RNA likes (piR-Ls), a novel type of functional sncRNAs, play key roles in chemoresistance to cisplatin (CDDP)-based chemotherapy in lung squamous cell carcinoma (LSCC). piR-L-138 was upregulated upon CDDP-based chemotherapy both in LSCC cells and in patient-derived xenograft (PDX) LSCC models. Further, targeting upregulated piR-L-138 led to increased apoptosis in CDDP-treated LSCC cells and LSCC xenograft mice treated with CDDP. In addition, piR-L-138 directly interacted with p60-MDM2 and inhibited CDDP-activated apoptosis in p53-mutated LSCC. We identified the upregulated piR-L-138 upon CDDP-based chemotherapy, confirmed the enhanced sensitivity of LSCC to agents by targeting the upregulated piR-L138 both in vitro and in vivo, and revealed mechanisms underlying piR-L-138 in chemoresistance, bolstering a new emerging clinical modality where novel functional piR-Ls provide potential strategies to overcome chemoresistance for patients with LSCC.
第一作者机构：[1]Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, 650 W. Baltimore St., Baltimore, MD21201, USA[2]Department of Thoracic Medical Oncology, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Peking University Cancer Hospital and Beijing Institute for Cancer Research, Beijing 100142, China
通讯作者：
通讯机构：[*1]Department of Oncology and Diagnostic Sciences, University of Maryland School of Dentistry, University of Maryland, 650 W. Baltimore St., Baltimore, MD 21201, USA
推荐引用方式(GB/T 7714)：
Yuyan Wang ,Tyler Gable ,Mark Z. Ma ,et al.A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma[J].MOLECULAR THERAPY-NUCLEIC ACIDS.2017,6:269-278.doi:10.1016/j.omtn.2017.01.003.
APA：
Yuyan Wang,,Tyler Gable,,Mark Z. Ma,,David Clark,,Jun Zhao,...&Yuping Mei.(2017).A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma.MOLECULAR THERAPY-NUCLEIC ACIDS,6,
MLA：
Yuyan Wang,,et al."A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma".MOLECULAR THERAPY-NUCLEIC ACIDS 6.(2017):269-278
医学